Bow Street’s Adamas Pharmaceuticals ADMS Stock Holding History

Bow Street’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$18.9M	Buy	1,153,022 +666,275	+137%	+$10.1M	36.13%	2
2016 Q2	$7.37M	Buy	+486,747	New	+$8.02M	21.31%	2
2015 Q4	–	Sell	-151,870	Closed	-$2.54M	–	28
2015 Q3	$2.54M	Buy	151,870 +25,000	+20%	+$569K	1.45%	18
2015 Q2	$3.33M	Buy	+126,870	New	+$2.47M	1.61%	20
2014 Q4	–	Sell	-88,560	Closed	-$1.65M	–	40
2014 Q3	$1.65M	Sell	88,560 -2,900	-3%	-$49.9K	0.59%	29
2014 Q2	$1.67M	Buy	+91,460	New	+$1.64M	0.56%	30

Other funds holding ADMS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

OTPPB

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Bow Street's ADMS Position: Q3 2016 in Review

Bow Street increased its Adamas Pharmaceuticals (ADMS) stake by 137% in Q3 2016, buying an estimated $10.1M and bringing the position to 1,153,022 shares worth $18.9M. The position accounts for 36.13% of the portfolio, ranked #2.

Bow Street first reported a position in ADMS in Q2 2014 and has held it in 6 quarters since. 81 funds tracked by Wall St. Rank hold ADMS as of Q3 2016.

Bow Street held 1,153,022 shares of Adamas Pharmaceuticals worth $18.9M as of Q3 2016.
Bow Street bought 666,275 Adamas Pharmaceuticals shares in Q3 2016, an estimated $10.1M.
Adamas Pharmaceuticals made up 36.13% of Bow Street's portfolio in Q3 2016, its #2 holding.
Bow Street first reported a position in Adamas Pharmaceuticals in Q2 2014 and has held it in 6 quarters since.
81 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2016.

Based on Bow Street's 13F filing for Q3 2016, filed 10 Nov 2016.